Renal replacement therapy for patients with diabetes mellitus in Hong Kong  by CHOY, Bo-Ying et al.
89
Hong Kong J Nephrol 2001;3(2):89-96. BY CHOY, et al
Renal replacement therapy for patients with diabetes mellitus in
Hong Kong
Bo-Ying CHOY1, Yiu-Wing HO2, Ka-Foon CHAU3, Chi-Bon LEUNG4, Wai-Kei TSANG5, Siu-Fai LUI4
Departments of Medicine, 1Queen Mary Hospital; 2United Christian Hospital; 3Queen Elizabeth Hospital;
4Prince of Wales Hospital; and 5Princess Margaret Hospital, Hong Kong.
Abstract
Diabetes mellitus is becoming the most common cause of end-stage renal failure in Hong Kong.
This review is based on data from the Hong Kong Renal Registry from 1995 through 2000. As of
March 31, 2000, a total of 1026 patients with diabetes mellitus were on renal replacement therapy.
A total of 809 patients had diabetic nephropathy as primary disease and 217 had diabetes mellitus
as comorbidity. The prevalence of renal replacement therapy for patients with diabetes mellitus
was 151 per million population. For the year ending March 31, 2000, there were 342 new patients
with diabetes mellitus requiring renal replacement therapy. Of all the patients on renal replacement
therapy, 23% were diabetic. The patients with diabetes mellitus were older (median age, 63 years),
and had a higher incidence of hypertension (85%), ischemic heart disease (24%), cerebrovascular
disease (9%), and peripheral vascular disease (3%). The modes of renal replacement therapy for
patients with diabetes mellitus were peritoneal dialysis (81%), hemodialysis (9%), and transplant
(10%). The annual crude mortality rate of patients with diabetes mellitus was 16% (peritoneal
dialysis, 17%; hemodialysis, 18%; transplant, 1%) compared with 6% for patients without diabetes
mellitus (peritoneal dialysis, 8%; hemodialysis, 12%; transplant, 1%). The major causes of death
were cardiovascular disease (33%), infection (28%), and cerebrovascular event (8%). The 1- and 5-
year survival rates of dibetic patient were 89% and 32% for peritoneal dialysis, 73% and 26% for
hemodialysis, and 94% and 87% for transplant, respectively. The 1- and 5-year graft survival
rates were 88% and 82% (death not censored), and 91% and 91% (death censored), respectively.
Key words: Diabetes mellitus (DM), Kidney transplantation (TX), Peritoneal dialysis (PD), Renal replacement
therapy (RRT), Survival analysis
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INTRODUCTION
Diabetes mellitus (DM) is becoming a major cause of
end-stage renal failure, which accounts for as many as
29% of new patients requiring renal replacement therapy
(RRT) in Hong Kong. The metabolic disturbance
associated with diabetes often leads to systemic
complications, which in turn may affect the treatment
outcome of these patients. Thus, data on this group of
patients deserve further analysis. In this review, we
analyze the treatment pattern and outcome of diabetic
patients who were receiving RRT in Hong Kong based
on data from the Hong Kong Renal Registry. The data
of all patients on RRT in Hong Kong from 1995 to 1999
have been published (1-3). The Hong Kong Renal
Registry has been implemented by the Hong Kong
Hospital Authority since 1995 and it accounts for
approximately 90% to 95% of all the patients on RRT
in Hong Kong.
METHODS
Data of all patients on RRT in Hong Kong during the
period from 1995 through 2000 were retrieved from the
Hong Kong Renal Registry. Data on patients with DM
nephropathy as primary renal disease (DM-N) and
patients with other primary renal disease but with DM
as comorbid disease (DM-C) were compared with data
for non-diabetic patients (non-DM). All clinical data were
censored on March 31 of each year. The annual crude
mortality rate was defined as the percentage of deaths of
a particular group of patients receiving a particular mode
of therapy during that year. For graft survival, patient
death with a functioning graft was counted as graft loss
in the “non-censored survival”, but was censored and
not counted as graft loss in “censored graft survival”.
Student’s t test, chi-square test, life table analysis, and
log-rank test were used where appropriate. A p value ≤0.01
was considered significant. Demographic data were
expressed as mean values ± standard error of the mean.
RESULTS AND DISCUSSION
Prevalence and incidence of renal
replacement therapy
The prevalence and incidence of RRT including
peritoneal dialysis (PD), hemodialysis (HD), and
transplantation (TX) for DM-N and DM-C patients are
summarized in Figures 1 and 2.
As of  March 31, 2000, a total of 4479 patients were on
RRT, of which 1026 were patients with DM (DM-N,
809; patients DM-C, 217 patients). The prevalence of
RRT for patients with DM was 151 per million population
and the percentage of patients on RRT with DM had
increased from 17% (DM-N, 12%; DM-C, 5%) in 1995
to 23% (DM-N, 18%; DM-C, 5%) in 2000.
For the year ending March 31, 2000, there were 1023
new patients started on RRT, of which 296 were DM-N
patients, accounting for 29% of new patients. As com-
pared with the previous year, the net increase in DM-N
patients was 10.8% compared with a 5.1% increase in
non-DM patients, indicating that DM-N is increasing at
a more rapid rate than other diagnoses as the cause of
end-stage renal disease.
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Figure 1. Number of prevalent cases of patients with diabetes
mellitus on renal replacement therapy from 1995 through 2000.
DM = diabetes mellitus
Figure 2. Number of new cases of patients with diabetes mellitus
started on renal replacement therapy from 1996 through 2000.
DM = diabetes mellitus
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Most of the patients with DM-C had glomerulonephritis
as the primary disease (Table 1). They accounted for 5%
of patients on RRT (PD, 6%; HD, 4%; TX, 4%), and the
percentage remained constant over the years.
Age and sex
The age distributions for DM and non-DM patients are
summarized in Figure 3A and B. As of March 31, 2000,
the mean age of patients with DM was 60.9 ± 0.4 years,
which was significantly older than the mean age of 50 ±
0.3 years for non-DM patients (p≤0.01). The median age
of DM patients was 63 years (TX, 56 years; HD, 63 years;
PD, 64 years) and the median age of the non-DM patients
was 49 years (TX, 43 years; HD, 50 years; PD, 56 years).
Of the new DM patients requiring RRT, 55% were more
than 61 years and 17% were more than 71 years of age
as compared with 30% more than 61 years and 11%
more than 71 years of age in the non-DM patients.
The trends of the median age of each group of patients
on RRT from 1995 through 2000 are shown in Figure
4A to C.
Table 1. Primary renal disease of patients with diabetes mellitus
as comorbidity as of March 31, 2000.
Primary renal disease Percentage of patients
Glomerulonephritis 36
Infection/reflux 4
Inherited/congenital 4
Obstructive/urolithiasis 11
Hypertension/vascular disease 7
Others 6
Unknown 32
Figure 3. Age distribution of (A) all patients with diabetes mellitus
(diabetic nephropathy and diabetes mellitus as comorbid) and (B)
all non-daibetic patients on renal replacement therapy as of March
31, 2000.
DM = diabetes mellitus; DM-C = diabetes mellitus as comorbid
disease; DM-N = diabetic nephropathy; HD = hemodialysis; PD =
peritoneal dialysis; TX = transplantation
A
B
Figure 4. Median age of patients on (A) peritoneal dialysis, (B)
hemodialysis, and (C) renal transplant.
DM = diabetes mellitus
A
B
C
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The male/female ratio was 1:1 (TX, 1:16; HD, 1:09; PD,
1:0.9) for DM patients, which was similar to the ratio of
1:1.1 (TX, 1:15; HD, 1:1.2; PD, 1:0.9) for non-DM patients.
Both groups had a male predominance in renal TX.
Comorbid conditions
Cardiovascular complications
As shown in Figure 5, patients with DM had significantly
more cardiovascular complications. The incidence of
hypertension (DM, 85% vs non-DM, 74%; p≤0.01),
ischemic heart disease (DM, 24% vs non-DM, 7%;
p≤0.01), cerebrovascular accident (DM, 9% vs non-DM,
3%; p≤0.01), and peripheral vascular disease (DM, 3%
vs non-DM, 0%; p≤0.01) were significantly higher in
DM patients than non-DM patients.
Hepatitis B and C infections
The proportion of DM patients who were serologically
positive for hepatitis B infection (DM, 9% vs non-DM,
10%) and hepatitis C infection (DM, 4% vs non-DM,
5%) were similar to non-DM patients (Fig. 5).
Mode of renal replacement therapy
As of  March 31, 2000, there were 1026 patients with
DM on RRT (DM-N, 809 patients; DM-C, 217 patients).
A total of 81% of the patients were on PD, 9% on HD,
and 10% had renal TX. The numbers of patients on
different modalities of treatment for DM and non-DM
patients are shown in Table 2 and Figure 6A and B.
As of March 2000, 33% of all patients on PD were
diabetic (DM-N, 27%; DM-C, 6%). The proportion had
Figure 5. Comorbid medical illness of patients on renal replacement
therapy.
CVA = cerebrovascular accident; DM = diabetes mellitus; HBV =
hepatitis B virus; HCV = hepatitis C virus; HT = hypertension; IHD
= ischemic heart disease; PVD = peripheral vascular disease
Table 2. Mode of renal replacement therapy for all patients as of 31 March, 2000.
All (%) DM patients (%) Non-DM patients (%)
RRT 4479 1026 3453
PD 2529 (57) 827 (81) 1702 (49)
HD 592 (13) 92 (9) 500 (15)
TX 1358 (30) 107 (10) 1251 (36)
DM = diabetes mellitus; HD = hemodialysis; PD = peritoneal dialysis; RRT = renal replacement therapy; TX = transplantation
Figure 6. Mode of renal replacement therapy for patients with (A)
diabetic nephropathy, and (B) diabetes mellitus as comorbidity.
DM = diabetes mellitus; HD = hemodialysis; PD = peritoneal dialysis;
TX = transplantation
A
B
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increased substantially from 23% in 1995 to 33% over
the last 5 years. Of the DM patients who were on dialysis,
90% were on PD. The percentage was higher than the
77% for the non-DM patients, showing that PD is the
predominant mode of RRT for patients with DM.
Hemodialysis
As of March 2000, 16% of all patients on HD were
diabetic (DM-N, 12%; DM-C, 4%) as compared with
8% in 1995. The amplitude of increase in the number
of diabetic HD patients was in line with that of PD
patients.
Transplantation
Of all the patients with renal transplant, 8% were diabetic
(DM-N, 4%; DM-C, 4%). For the 12 months ending
March 31, 2000, only 12 patients (DM-N, 7 patients;
DM-C, 5 patients) received renal transplant. This was
only 7% of the total of 182 patients who had received
transplant during this period. The current database could
not differentiate de novo or drug-induced DM. However,
judging from the small percentage of transplant patients
(4%) having DM as comorbid factor, the incidence of
steroid-induced DM after transplant would be low.
For the year 2000, a total of 1002 patients were on
transplant waiting list, of which 114 patients were
diabetic (DM-N, 88 patients; DM-C, 26 patients). Only
12% of DM patients on dialysis were put on transplant
waiting list as compared with 40% in non-DM patients.
The older age and higher incidence of cardiovascular
complications had rendered DM patients less suitable
candidates for renal TX.
Outcome indicators
Annual crude mortality rates
For the 12 months ending March 31, 2000, the annual
crude mortality rate was 16% for DM-N patients on RRT
(PD, 16%; HD, 21%; TX, 2%), 14% for DM-C patients
(PD, 20%; HD, 5%; TX, 0%), and 6% for non-DM
patients (PD, 8%; HD, 12%; TX, 1%). The annual crude
mortality rates for DM-N and DM-C patients were
similar (p=0.45). However, both DM-N and DM-C
patients had significantly higher mortality rates than the
non-DM patients (p≤0.01). The annual crude mortality
rates are summarized in Figure 7A to C.
The main causes of death for patients with DM were
cardiovascular disease (DM, 33% vs non-DM, 23%),
infection (DM, 28% vs non-DM, 33%), and cerebrovas-
cular accident (DM, 8% vs non-DM, 6%) (Table 3).
Patients with DM had more frequent fatal cardiovascular
events than non-DM patients.
Peritoneal dialysis patient survival rates
The 1- and 5-year patient survival rates for DM patients
receiving PD were 89% and 32%, respectively. The
survival rates of DM patients were significantly lower
than non-DM patients, whose 1- and 5-year survival rates
were 95% and 64%, respectively (p≤0.01) (Fig. 8).
Hemodialysis patient survival rates
The 1- and 5-year patient survival rates for DM patients
Figure 7. Annual crude mortality rate of (A) patients with diabetic
nephropathy, (B) patients with diabetes mellitus as comorbidity,
and (C) non-DM patients on renal replacement therapy from 1996
to 2000.
HD = hemodialysis; PD = peritoneal dialysis; TX = transplantation
A
C
B
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Figure 9. Hemodialysis 1- to 5-year patient survival rates.
DM = diabetes mellitus; DM-N = diabetic nephropathy
on HD were 73% and 26%, respectively, which were
significantly lower than the 91% and 71% of 1- and 5-
year patient survival rates, respectively, of non-DM
patients (p≤0.01) (Fig. 9). In Hong Kong, all patients
requiring RRT were offered PD as the first modality of
treatment. Approximately 84% of HD patients, both for
DM and non-DM, had failed PD treatments. The poorer
survival rates of the DM patients reflect their poor
tolerance to HD, which may be attributed to their older
age and poorer cardiovascular status.
Transplant survival rates
Transplant patient survival rates
During the period of April 1, 1995 through March 31,
1999, a total of 37 patients with DM received renal TX.
Thirty-three transplants were from cadaveric donors and
four from living donors. The 1- and 5-year patient
survival rates calculated up to March 31, 2000 were 94%
and 87%, respectively, as compared with 97% and 92%
for non-DM patients (379 cadaveric donors, 107 living
donors), the differences of which were not significant.
The results should be treated with caution because only
a few well-selected DM patients had received renal TX.
The survival rates of the patients with death on transplant
and death on transplant history are summarized in Figure
10A and B.
Transplant graft survival rates
The 1- and 5-year graft survival rates for DM patients
receiving cadaveric renal transplant were 93%, 93%
(death censored) and 90%, 82% (death not censored),
respectively. The 1- and 5-year cadaveric graft survival
rates for non-DM patients were 91%, 82% (death
censored) and 89%, 76% (death not censored), respectively.
The differences in the graft survival rates for DM and
non-DM patients were not significant.
There were only four living donor transplants performed
for patients with DM. The 1- and 5-year graft survival
rates were both 75% (both death censored and not
censored). The living graft survival rates for non-DM
Table 3. Cause of death for all diabetes mellitus  and non-diabetes mellitus patients for the 12 months ending March 31, 2000.
DM patients Non-DM patients
PD HD TX All (%) PD HD TX All (%)
Cardiovascular 56 7 0 63 (33) 35 17 2 54 (23)
Cerebrovascular 14 2 0 16 (8) 7 6 1 14 (6)
Liver failure 0 0 0 0 (0) 2 0 2 4 (2)
Infection 50 2 1 53  (28) 50 23 4 77 (33)
Malignancy 4 0 0 4 (2) 6 4 1 11 (5)
Termination/failure 3 0 0 3 (2) 8 1 0 9 (4)
Others 18 2 0 20 (10) 17 10 1 28 (12)
Unknown 25 7 0 32 (17) 24 7 4 35 (15)
Total 170 20 1 191 149 68 15 232
DM = diabetes mellitus; HD = hemodialysis; PD = peritoneal dialysis; TX = transplantation
Figure 8. Peritoneal dialysis 1- to 5-year patient survival rates.
DM = diabetes mellitus; DM-N = diabetic nephropathy
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patients during the same period were 94%, 85% (death
censored) and 93%, 84% (death not censored),
respectively. The graft survival rates for different
subgroups of patients are summarized in Figure 11A
and B.
Peritonitis rates
For the 12 months ending March 31, 2000, the overall
peritonitis rate for all continuous ambulatory peritoneal
dialysis connection systems for both DM and non-DM
patients was one episode per 27 months. The peritonitis
rates were comparable for both groups of patients.
CONCLUSION
Diabetes mellitus is becoming the most common cause
of end-stage renal failure in Hong Kong. The number of
DM patients requiring RRT is increasing at a rate of
approximately 10% per year. Patients with DM are older
and have more cardiovascular complications. The
predominant mode of RRT for DM patients is PD.
Figure 10. Renal transplantation 1- to 5-year patient survival rates.
(A) Death on transplant; (B) death on transplant history.
DM = diabetes mellitus; DM-N = diabetic nephropathy; Hx TX =
transplant history; TX = transplantation
A
B
Patient survival rates for all modalities of dialysis therapy
are poorer for patients with DM. Only 10% of patients
with DM have received renal TX. The patient and graft
survival rates for TX are comparable to non-DM patients,
but the results should be treated with caution because
only a few well-selected DM patients have received renal
TX.
Because the number of DM patients requiring RRT is
increasing in Hong Kong and their outcomes are poorer,
the medical community should intensify efforts on stricter
glycemic control and more aggressive blood pressure
reduction, preferably with angiotensin converting enzyme
inhibitors, for patients with diabetes. Both measures have
been shown to prevent the development and retard the
progression of diabetic nephropathy (4-6).
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